Positron Emission Tomography (PET) Imaging of Lung Cancer Response to Therapy in Patients Registered to S9900

Patients must have a histologic diagnosis of Stage IB (T2N0), II (T1-2N1, T3N0) and selected Stage IIIA (T3N1) NSCLC and be registered to the chemotherapy arm (Arm 2) of S9900; all institutions must have attentuation-corrected PET imaging with [F-18] FDG available for use; pts. must already have undergone PET scanning (meeting the criteria outlined in Sections 4.1 and 12.2) prior to enrollment on this protocol and randomization to S9900, and within 21 days prior to beginning of chemotherapy; baseline PET imaging must have been done in accordance with Sections 4.1 and 12.2 in order to calculate pre-tx SUV; pts. must have no history of diabetes, and must not be on insulin or oral hypoglycemic agents; pts. must have a fasting glucose < 150 mg/dl immediately prior to PET scan; pts. must agree to have specimens submitted as outlined in Section 4.4; however, pts. are strongly encouraged to register to and have specimens submitted per S9925.